CoChat

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Open access

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Oncogenic alterations in the RAS/RAF/MEK/ERK pathway drive the growth of a wide spectrum of cancers. While BRAF and MEK inhibitors are efficacious against BRAF V600E-driven cancers, effective targeted therapies are lacking for most cancers driven by other pathway alterations, including non-V600E oncogenic BRAF, RAS GTPase-activating protein (GAP) NF1 (neurofibromin 1) loss and oncogenic KRAS. Here, we show that targeting the SHP2 phosphatase (encoded by PTPN11) with RMC-4550, a small-molecule allosteric inhibitor, is effective in human cancer models bearing RAS-GTP-dependent oncogenic BRAF (for example, class 3 BRAF mutants), NF1 loss or nucleotide-cycling oncogenic RAS (for example, KRAS G12C). SHP2 inhibitor treatment decreases oncogenic RAS/RAF/MEK/ERK signalling and cancer growth by disrupting SOS1-mediated RAS-GTP loading. Our findings illuminate a critical function for SHP2 in promoting oncogenic RAS/MAPK pathway activation in cancers with RAS-GTP-dependent oncogenic BRAF, NF1 loss and nucleotide-cycling oncogenic KRAS. SHP2 inhibition is a promising molecular therapeutic strategy for patients with cancers bearing these oncogenic drivers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41556-018-0169-1

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 2

  1. McDonald, E. R.III et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577–592.e10 (2017). · DOI · Paper page
  2. Koltun, E. & Revolution Medicines, Inc. (WO2018013597) 2,5-Disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors. Patent no. PCT/US2017/041577 (2017); https://go.nature.com/2mv9pBw

Cited by

See all 425

Metadata

Authors
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., Hsieh, T., Zaman, A., Olivas, V., McCoach, C., Blakely, C. M., Wang, Z., Kiss, G., Koltun, E. S., Gill, A. L., Singh, M., Goldsmith, M. A., Smith, J. A. M., & Bivona, T. G.
Affiliations
  • Revolution Medicines (United States) (US)
  • University of California, San Francisco (US)
Corresponding author
  • Smith, Jacqueline A. M.
  • Bivona, Trever G.
Venue
Nature Cell Biology
Published
2018-08-13
Volume
20
Issue
9
Pages
1064-1073
ISSN
  • 1465-7392 (ISSN-L)
  • 1476-4679
OpenAlex
W2887730046
Cited by
415
References
47
Citations by year
2026: 31 · 2025: 37 · 2024: 70 · 2023: 63 · 2022: 68 · 2021: 60 · 2020: 54 · 2019: 30 · 2018: 2
FWCI
13.09
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature Cell Biology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Doris Duke Charitable Foundation (2018110)
  • National Cancer Institute (R01CA169338, DP2CA174497, U01CA217882, R01CA211052, R01CA204302, U54CA196519, U54CA224081)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
SHP2, PTPN11, SOS1, oncogenic BRAF, NF1 loss, KRAS G12C, RAS/MAPK pathway, allosteric inhibitors, targeted cancer therapy, MAPK signaling
MeSH terms
Animals, Antineoplastic Agents, Enzyme Inhibitors, Guanosine Triphosphate, Humans, Mice, Inbred BALB C, Mice, Nude, Mutation, Neoplasms, Phenotype, Biomarkers, Tumor, Signal Transduction, Proto-Oncogene Proteins p21(ras), Genetic Predisposition to Disease, SOS1 Protein, Mitogen-Activated Protein Kinase Kinases, Xenograft Model Antitumor Assays, Neurofibromin 1, Cell Line, Tumor, Tumor Burden, Extracellular Signal-Regulated MAP Kinases, raf Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. https://app.cochat.ai/papers/10.1038/s41556-018-0169-1
The paper
Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., Hsieh, T., Zaman, A., Olivas, V., McCoach, C., Blakely, C. M., Wang, Z., Kiss, G., Koltun, E. S., Gill, A. L., . . . Bivona, T. G. (2018). RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology. https://doi.org/10.1038/s41556-018-0169-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.